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Summary Women with carcinoma in situ (CIS) of the cervix uteri, notified to the population-based Cancer
Registry of the Swiss Canton of Vaud between 1974 and 1993, were actively followed up to 31 December 1993
for the occurrence of subsequent invasive neoplasms. Among 2190 incident cases of CIS, followed for a total of
22 225 person-years, 95 metachronous cancers were observed vs 77.9 expected, corresponding to a significant
standardised incidence ratio (SIR) of 1.2. Ten cases of invasive cervical cancer were observed vs 3.0 expected
(SIR = 3.4, P<0.01), the excess being larger in the first 10 years since CIS diagnosis. A total of 11 cases of four
major tobacco-related sites (lung, mouth or pharynx, oesophagus and urinary bladder) were observed vs 5.1
expected, corresponding to a significant SIR of 2.2. The excess was observed > 10 years after CIS diagnosis.
There was also an excess of non-melanomatous skin cancers (29 observed, 16.9 expected, SIR= 1.7; P<0.01),
but not of skin melanoma and of any of the other neoplasms considered, including breast and corpus uteri.
This population-based study, therefore, finds an excess of invasive cervical cancer in the short term after CIS
diagnosis, and a medium- to long-term excess risk of tobacco-related and non-melanomatous skin neoplasms.
These findings are discussed in terms of increased surveillance and case ascertainment after CIS, and of
potential shared risk factors (tobacco and/or viral infections).
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Women diagnosed with carcinoma in situ (CIS) of the cervix
uteri constitute a selected population with reference to (1)
their subsequent risk of invasive cervical cancer and (2) their
incidence of other neoplasms, which may share risk factors
with cervical carcinogenesis, or whose diagnosis may be
influenced by the changed medical surveillance after CIS.
Only scattered data, however, are available on the issue. A
study of cervical carcinoma in situ registered in Norway
between 1970 and 1992 (Bjorge et al., 1995) found no overall
excess of cancer, but elevated rates for lung, oesophagus,
nose, bladder and the urinary organs (i.e. major tobacco-
related neoplasms), vulva and vagina, and skin (squamous
cell). Uterine cancer rates (cervix and corpus) were lower
than expected. No excess risk of cutaneous melanoma was
registered in a study of cervical intraepithelial neoplasia from
Washington State (Schmulewitz et al., 1993).
To provide further quantitative information on these open
issues, we have linked data from 2190 women with in situ
carcinoma of the cervix, registered by the Swiss Cancer
Registry of Vaud between 1974 and 1993, with cancer
incidence data from the same registry, with specific focus
on cervical cancer, major tobacco-related neoplasms (since
tobacco may influence cervical carcinogenesis; Winkelstein,
1990; Brinton, 1992), skin cancer [which may be linked to
viral infections (IARC, 1995) or influenced by detection
accuracy], and, for comparative purposes, other cancer sites.
Materials and methods
Data for the present report were abstracted from the Vaud
Cancer Registry file, which includes incident cases of
malignant neoplasms in the canton (Levi et al., 1992) whose
population, according to the 1990 census, was about 600 000
inhabitants. The registry file is tumour based, and multiple
primaries in the same person are entered separately. Most
cases are registered repeatedly and from different institutions,
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thus improving completeness and accuracy of registration.
The basic information available from the register comprises
sociodemographic characteristics of the patient (i.e. age and
sex), primary site and histological type of the tumour
according to the standard International Classification of
Diseases for Oncology (ICD-O; World Health Organization,
1976), and time of diagnostic confirmation (histological or
clinical diagnosis). Passive and active follow-up is recorded,
and each subsequent item of information concerning an
already registered case is used to complete the record of that
patient.
Since 1974, a registration scheme, applying the same
standardised rules as for incident malignancies, has been
implemented for carcinoma in situ and severe dysplasia of the
uterine cervix (CIN III). All histological reports were
scrutinised and reviewed when reporting a diagnosis of CIS.
After exclusion of all synchronous CIS and other cancers
Table I Age distribution of 2190 cases of histologically verified in
situ carcinoma (CIS) of uterine cervix, corresponding incidence rates
and person-years at risk by time since diagnosis (Vaud, Switzerland,
1974-93)
Carcinoma in situ, n Rate per 100 000
Age group (years)
0-19
20-29
30- 39
40-49
50- 59
60-69
70- 79
80 +
Total, all ages
16
642
859
412
135
87
30
9
2190
1.0
77.7
101.0
54.8
21.9
16.0
7.1
3.3
34.9a
Time since diagnosis Person-years at risk
(years) by time since diagnosis
1-4 9319
5-9 7035
10-14 4438
15+ 1433
Total 22 225
a Age-standardised rate on the world population.
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Table II Observed (0) and expected (E) second primary cancers or groups of cancers following 2190 cases of in situ
carcinoma of the uterine cervix according to time since diagnosis, and corresponding overall standardised incidence ratios
(SIR) (Vaud, Switzerland, 1974-93)
Years since diagnosis Whole period
Site 1-4 5-9 10-14 15+ SIR (95%
CI)
Mouth of pharynx 0 1 1 4 5 1,1
oesophagus, lung, bladder E 1.5 1.6 1.4 0.6 5.1 2.2 (1.1-3.9)
Skin, non-melanoma 0 5 10 9 5 29
E 5.1 5.3 4.5 1.9 16.9 1.7 (1.1-2.5)
Skin, melanoma 0 1 1 0 1 3
E 1.1 1.0 0.8 0.3 3.2 0.9 (0.2-2.7)
Breast (females) 0 3 6 7 2 18
E 7.3 7.8 6.5 2.6 24.4 0.8 (0.4-1.2)
Cervix uteri 0 6 3 1 0 10
E 1.0 0.9 0.7 0.3 3.0 3.4 (1.6-6.3)
Corpus uteri 0 3 0 1 1 5
E 1.0 1.1 1.0 0.5 3.5 1.4 (0.5-3.3)
Other sites 0 6 8 3 2 19
E 7.0 7.2 6.2 2.7 23.1 0.8 (0.5-1.3)
Total, all sites 0 25 29 25 16 95
E 23.8 24.8 20.7 8.7 77.9 1.2 (1.0-1.5)
(n= 8, i.e. two cancers of the breast, four of the uterine corpus,
one of the ovary and one of unspecified genital organs), the
present series comprises a total of 2190 histologically (at least
through a biopsy) confirmed CIS. The age range was 18-92
years (median age, 34 years). These cases of incident CIS were
followed up to the end of 1993, for the occurrence of cancer,
migration or death. Histological confirmation was performed
in 100% of both the CIS and of the second primaries.
Calculation of expected numbers was based on site-, age-
and calendar year-specific incidence rates, multiplied by the
observed number of person-years at risk. The significance of
the observed/expected ratios (standardised incidence ratio,
SIR), and the corresponding 95% confidence interval (CI),
was based on the exact Poisson distribution (Breslow and
Day, 1987).
Results
Table I gives the distribution of 2190 cases of CIS according to
age, the corresponding incidence rate for the whole calendar
period, and the person-years at risk in separate intervals of
time since diagnosis, for a total of 22 225 person -years at risk.
Table II gives the observed and expected numbers of all
neoplasms and of selected cancer sites in separate strata of
years since diagnosis. Overall, 95 metachronous cancers were
observed vs 77.9 expected, corresponding to a significant SIR
of 1.2. The excess was larger 15 years or more after CIS
diagnosis (16 observed, 8.7 expected, SIR = 1.8). Ten cases of
invasive cervical cancer were observed vs 3.0 expected
(SIR=3.4), the excess incidence being largest in the first 5
years (six observed, one expected), and between 5 and 9 years
(three observed, 0.9 expected) since CIS diagnosis, and
levelling off thereafter.
Four major tobacco-related sites (lung, mouth or pharynx,
oesophagus and urinary bladder) were grouped together. A
total of 11 cases (one of the mouth or pharynx, one of the
oesophagus, seven of the lung, and two of the bladder) were
observed, vs 5.1 expected, corresponding to a significant SIR
of 2.2. The excess was greater 10 years or longer after CIS
diagnosis (four observed, 1.4 expected, SIR= 2.9, between 10
and 14 years; five observed, 0.6 expected, SIR= 8.3, > 15
years). There was also an excess of non-melanomatous skin
cancers (29 observed, 16.9 expected, SIR = 1.7), the elevated
risk being greatest 5 years after CIS diagnosis or longer, but
not of skin melanoma (three observed vs 3.2 expected,
SIR = 0.9). None of the other neoplasms considered,
including breast (SIR=0.8), corpus uteri (SIR= 1.4) or
other miscellaneous sites (SIR= 0.8) showed excess incidence
in women with CIS.
Discussion
In this population, there was an excess of invasive cervical
cancer following histologically confirmed CIS, which was
however restricted to the 10 years after CIS diagnosis. This
may partly be due to increased ascertainment but underlines
the importance of adequate treatment and surveillance of
women after CIN (La Vecchia et al., 1995).
There was also a significant excess of tobacco-related
neoplasms, which became evident 10 years after CIS
diagnosis. This may be interpretable in terms of shared risk
factors, since a role of tobacco in cervical carcinogenesis has
long been suspected (Winkelstein, 1977; Brinton, 1992). In a
review of 33 epidemiological studies of the relationship between
cigarette smoking and cancer of the uterine cervix published
over the last three decades (Winkelstein, 1990), 26 found a
direct association. This association has also been reported for
cervical intraepithelial neoplasia (including CIN III; Parazzini
et al., 1992, 1996; Szarewski et al., 1996). Furthermore, nicotine
and cotinine have been identified in cervical mucus, and their
concentration was directly related to cigarette smoking
(Hellberg et al., 1988; Schiffman et al., 1987; McCann et al.,
1992).
A significant excess of lung cancer was also observed
following invasive cervical cancer in the same population
(Levi et al., 1993a), and rates from several tobacco-related
neoplasms were also elevated in a large study of in situ
cervical cancer from Norway (Bjorge et al., 1995). Likewise,
an increase for lung and bladder cancer incidence was
observed in Denmark (Storm and Ewertz, 1985; Storm,
1988), and for lung, oral cavity, larynx and bladder in
Connecticut following cervical cancer (Rabkin et al., 1992).
It is also possible that human papilloma virus (HPV), the
major identified risk factor for cervical neoplasms, is related
to oral and pharyngeal, and, possibly, squamous cell
carcinomas from other epithelia (IARC, 1995; Franceschi et
al., 1996; Maden et al., 1992; Benamouzig et al., 1992;
Gissmann et al., 1983).
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The (non-melanomatous) skin cancer excess in the medium
to long term following a CIS is more difficult to understand
(although it has also been reported in other studies; Hartveit,
1988; Bjorge et al., 1995). In this study, ascertainment bias is
unlikely, since the excess risk became evident five or more
years after CIS diagnosis. Again HPV (IARC, 1995), or
subtle immunological impairment, may be aspects shared by
cervical and skin carcinogenesis. A confounding effect of
some lifestyle habits, chiefly recreational sun exposure,
cannot be excluded.
Among the strengths of the study, there are its population
basis, which should render any estimate relatively free from
selection bias (Levi et al., 1993b) and the complete
histological confirmation of CIS cases. The absence of
association with any of the other cancer sites is also
reassuring with respect to surveillance bias, and provides
relevant indications for the potential focus on a preventive
and early diagnosis level for women diagnosed with CIS.
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